Meeting
2012 ASCO Annual Meeting
Frequency and clinical characterization of NSCLC patients harboring PIK3CA mutations identified within a regional screening network.
Authors
Masyar Gardizi
Lung Cancer Group Cologne, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
Masyar Gardizi , Matthias Scheffler , Lukas Carl Heukamp , Marc Christiaan Allardt Bos , Kerstin Albus , Birgit Hayn , Yon-Dschun Ko , Andreas Schlesinger , Michael Brockmann , Monika Heidi Serke , Ulrich Gerigk , Khosro Hekmat , Erich Stoelben , Marcel Reiser , Roland Schnell , Stephan H. Schmitz , Konrad Frank , Reinhard Buettner , Jurgen Wolf , Thomas Zander
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Other
Citation
J Clin Oncol 30, 2012 (suppl; abstr 10526)
DOI
10.1200/jco.2012.30.15_suppl.10526
Abstract #
10526
Poster Bd #
19
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Regional screening network for characterization of the molecular epidemiology of non-small cell lung cancer (NSCLC) and implementation of personalized treatment.
First Author: Thomas Zander
Poster
2016 ASCO Annual Meeting
Genetic heterogeneity of KRAS-mutated NSCLC: Co-occurrence of potentially targetable aberrations and evolutionary background.
First Author: Matthias Scheffler
Poster
2014 ASCO Annual Meeting
Implementation of clinical next-generation sequencing (NGS) of non-small cell lung cancer (NSCLC) to identify EGFR amplification as a potentially targetable oncogenic alteration.
First Author: Geoffrey R. Oxnard
Poster
2014 ASCO Annual Meeting
Next-generation sequencing (NGS) to identify actionable genomic alterations (GA) in “pan-negative” lung adenocarcinomas (ADC) from patients with no smoking or a light smoking (NS/LS) history.
First Author: Alexander E. Drilon